Login to Your Account



Pharma: Other News To Note


Friday, October 5, 2012

• Pfizer Inc., of New York, reported top-line data assessing the immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age. The study's primary objective was to demonstrate that the immune response to Prevenar 13 in the 18- to 49-year-old age group is noninferior to the compound's immune response in the 60- to 64-year-old age group as measured by serotype-specific opsonophagocytic assay titers one month after vaccination.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription